Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sezary Syndrome Patient.

ABSTRACT:

Background

Sézary syndrome (SS) is a rare lymphoproliferative neoplasm, almost incurable outside the setting of allogeneic transplantable patients. The prognosis for relapsed/refractory patients remains poor, as the available drugs confer short-lasting remission. In this setting, the anti-chemokine receptor type 4 (CCR4) monoclonal antibody mogamulizumab demonstrated efficacy in an international, open-label, randomized controlled phase 3 trial (MAVORIC) versus vorinostat.

Case description

A heavily pretreated 57-year-old SS woman (stage IVA) was randomized in the mogamulizumab arm of MAVORIC at our Institution. She quickly achieved a response, but after 30 cycles, she was discontinued from therapy due to cutaneous toxicity. Nevertheless, she is still in complete response (CR

SUBMITTER: Lolli G 

PROVIDER: S-EPMC7340218 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature